| Bioactivity | SACLAC, a Ceramide analog, is a potent and covalent acid ceramidase (ASAH1; AC) inhibitor with a Ki of 97.1 nM. SACLAC effectively blocks AC activity and induces a decrease in sphingosine 1-phosphate and total ceramide levels. SACLAC reduces the levels of splicing factor SF3B1 and alternative Mcl-1 mRNA splicing, increases pro-apoptotic Mcl-1S levels to induce apoptosis in acute myeloid leukemia (AML) cells. SACLAC reduces the leukemic burden in human AML xenograft mouse models[1][2]. |
| CAS | 2248703-42-4 |
| Formula | C20H40ClNO3 |
| Molar Mass | 377.99 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yadira F Ordóñez, et al. Activity-Based Imaging of Acid Ceramidase in Living Cells. J Am Chem Soc. 2019 May 15;141(19):7736-7742. [2]. Jennifer M Pearson, et al. Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia. Mol Cancer Res. 2020 Mar;18(3):352-363. |